Healthy Lactating Mother Clinical Trial
Official title:
Effects of Multiple Micronutrients, Lutein and Docosahexaenoic Acid (DHA) Supplementation During Lactation on Human Milk Nutrient Content, Maternal Blood Biomarkers and Infant Anthropometric Parameters
| NCT number | NCT04462939 |
| Other study ID # | 18737 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | April 26, 2017 |
| Est. completion date | November 12, 2019 |
| Verified date | July 2020 |
| Source | Bayer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of the study is to learn about the effect of multi-micronutrient, lutein and DHA
supplementation (Elevit Breastfeeding & Postnatal Care) on the breast milk nutrient
composition and babies physical growth parameters.
Mothers participating in this study received either Elevit or placebo orally once a day for
12 weeks starting from 4 to 6 weeks after delivery. Blood, urine and milk samples were
collected from the mothers and physical parameters like size and weight were collected from
the babies to assess the effect of the supplementation.
| Status | Completed |
| Enrollment | 68 |
| Est. completion date | November 12, 2019 |
| Est. primary completion date | November 12, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria for women: - Healthy pregnant women aged 18 to 45 years (inclusive) in their third trimester of pregnancy who are expected to give birth to a healthy single full-term infant; - Hb > 105 g/L; - Intention to breastfeed for at least four months (no more than one bottle or 10% of total milk intake daily as formula); - Omnivorous diet; - Not intent to take multivitamin supplements, DHA supplements, lutein supplements or any combination of the aforementioned after giving birth except for iodine and iron; - Seronegative for Human Immunodeficiency Virus (HIV), Hepatitis B, and Hepatitis C at screening; - Pregnant women who, in the opinion of the Investigator, are willing and able to participate in all scheduled visits, to adhere to the study plan, to laboratory tests and to all other study related procedures according to the clinical protocol; - Pregnant women providing a personally signed and dated informed consent willing to participate in the study and to adhere to all study procedures including the assessments done to the infant, indicating that they have been informed of all pertinent aspects of the trial and that they understood and accepted these, prior to admission to the study. Inclusion Criteria for infants: - Full term/gestational age > 37 weeks < 43 weeks and birth weight adequate for gestational age; - Apgar score at 5 minutes after birth > 7; - No indication of abnormal neurodevelopment. Exclusion Criteria for women: - Physical (including vital signs e.g. blood pressure, pulse rate), hematological and clinical-chemical parameters deviating from normal and with clinical relevance in the opinion of the investigator; - Any serious infection (acute or chronic) at screening and randomization; - Any history of or current metabolic diseases (e.g. diabetes, hypothyroidism, and other metabolic diseases); - Less than 12 months from previous delivery; - Any history of or current diseases, which are associated with malabsorption, or other severe diseases of the gastrointestinal tract (e.g. chronic inflammatory bowel disease, iron accumulation, iron utilization disorders); - Any history of or current neurological, cardiac, endocrine or bleeding disorders; - Specific diets (e.g. vegan, vegetarian, celiac); - Pre-pregnancy body mass index (BMI) < 18.5 or > 30 kg/m2; - Diagnosed or suspected malignant or premalignant disease; - Current clinically significant depression; - Not willing, or unable for medical reasons to interrupt any intake of pharmaceuticals or dietary supplements which may interact with any of the ingredients of the trial product (i.e. fluoroquinolones, bisphosphonates, levodopa, levothyroxine, penicillamine, antibiotics containing tetracycline or trietine) during the study supplementation period (From Visit 2 (Randomization) until Visit 4 (EoS)); - History of or current diseases where vitamin, mineral, trace element, lutein or DHA supplementation might be not recommended / contraindicated (such as sickle cell anemia, copper metabolism disorders (Wilson's disease), renal disease, nephrolithiasis, urolithiasis, hypercalcemia, hypercalciuria, hepatobiliary diseases, existing hypervitaminosis, iron metabolism disorders, hypermagnesemia); - Any pregnancy complications or adverse pregnancy outcomes in current pregnancy that may affect micronutrient metabolism or status (e.g. preeclampsia, eclampsia, polyhydramniosis, placental insufficiency); - Diagnosed congenital abnormalities in current pregnancy; - Current smoker or smoker during current pregnancy. Main exclusion criteria for infants: - Congenital anomalies; - Obvious gastrointestinal or metabolic disorders; - Perinatal hypoxia; - Preterm birth; - Very low birth weight (VLBW). |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Praxis Fr. Dr. K. Maar | Berlin | |
| Germany | Gynäkologische Gemeinschaftspraxis Freising | Freising | Bayern |
| Germany | Praxis Hr. E. Goeckeler-Leopold | Geseke | Nordrhein-Westfalen |
| Lead Sponsor | Collaborator |
|---|---|
| Bayer |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from baseline in human milk total lipid docosahexaenoic acid (DHA) content: % DHA concentration relative to total milk | The primary endpoint will be analyzed using the analysis of covariance (ANCOVA) with supplementation as fixed effect and baseline value as covariate. | At Baseline and 6 weeks and 12 weeks | |
| Secondary | Change from baseline in blood parameters: % concentration relative to total milk | Fatty acids (FA) in plasma and glycerophospholipids (GPL); DHA/total fatty acid (TFA) ratio; IFN-gamma; TGF-beta; Folic acid, Vitamin B12 and homocystein; 25-Hydroxivitamin D; Alpha-tocopherol and retinol; Carotenoids (lutein, zeaxanthin, beta-cryptoxanthin, lycopene, carotene) | At Baseline and 6 weeks and 12 weeks | |
| Secondary | Change from baseline in milk parameters: % concentration relative to total milk | Total lipids; DHA/total FA ratio; Milk macronutrient content; IFN-gamma; TGF-beta; Alpha-tocopherol and retinol; Carotenoids (lutein, zeaxanthin, beta-cryptoxanthin, lycopene, carotene) | At Baseline and 6 weeks and 12 weeks | |
| Secondary | Change from baseline: maternal height | At Baseline and 12 weeks | ||
| Secondary | Change from baseline: maternal weight | At Baseline and 12 weeks | ||
| Secondary | Change from baseline: Maternal BMI kg/m2 | At Baseline and 12 weeks | ||
| Secondary | Change from baseline: Maternal fatigue questionnaire | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Change from baseline: Maternal food frequancy questionnaire | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Change from baseline: Infant weight | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Change from baseline: Infant length | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Change from baseline: Infant Calculation of Weight Standard Deviation Scores (SDS) | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Change from baseline: Infant Calculation of Length Standard Deviation Scores (SDS) | At Baseline and 6 weeks and 12 weeks | ||
| Secondary | Number of Adverse Events (AEs) | Up to 13 weeks | ||
| Secondary | Severity of AEs | Up to 13 weeks | ||
| Secondary | AE relationship to the investigational product | Up to 13 weeks |